☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Cullinan Oncology
The US FDA Clears Cullinan Oncology’s IND Application of CLN-619 for Treating R/R Multiple Myeloma
March 4, 2024
Cullinan Oncology Entered into an Exclusive License with Harbour BioMed to Develop and Commercialize HBM7008 (CLN-418) in the US
February 14, 2023
Load more...
Back to Home
Modal title
×
Modal body text goes here.
